ATS 2020 Advance Program

• better define the indications for home oxygen therapy based on the patients' underlying conditions. This symposium presents 3 controversial areas in the diagnosis and/or management of common conditions: a) the need to perform a lung biopsy and/or treat every infant with suspected ILD regardless of their clinical condition; b) the need to treat with antibiotics, organisms that are considered to be physiologic “oral flora” when they are present in the BAL, c) the adoption of a universal “cut-off” value of oxygen saturation that will determine whether supplemental oxygen is needed. Chairing: A.C. Koumbourlis, MD, MPH, ATSF, Washington, DC S.A. McGrath-Morrow, MD, Baltimore, MD 2:15 Introduction A.C. Koumbourlis, MD, MPH, ATSF,Washington, DC 2:18 PRO: A Lung Biopsy Is Needed Before Initiating Treatment for Suspected ILD Speaker To Be Announced 2:36 CON: A Lung Biopsy Is Needed Before Initiating Treatment for Suspected ILD L.R. Young, MD, ATSF, Philadelphia, PA 2:54 PRO: Organisms From “Normal” Oral Flora Should Always Be Treated if Found in BAL Speaker To Be Announced 3:12 CON: Organisms From “Normal” Oral Flora Should Always Be Treated if Found in BAL A. Hahn, MD, Washington, DC 3:30 PRO: Supplemental Oxygen Should Be Orescribed on the Basis of a “Cut-Off” Value of HbSaO2 I.M. Balfour Lynn, MD, London, United Kingdom 3:48 CON: Supplemental Oxygen Should Be Prescribed on the Basis of a “Cut-Off” Value of HbSaO2 V. Balasubramaniam, MD, Madison, WI 4:06 Discussion S.A. McGrath-Morrow, MD, Baltimore, MD CLINICAL SCIENTIFIC SYMPOSIUM A88 THREE IN ONE: UPDATES ON ASTHMA MANAGEMENT FROM 3 GUIDELINE COMMITTEES Assemblies on Allergy, Immunology and Inflammation; Behavioral and Health Services Research; Clinical Problems 2:15 p.m. - 4:15 p.m. Target Audience Providers of asthma care; those with clinical research, or administrative responsibilities in asthma; those involved in developing asthma guidelines; those involved in quality improvement or value-based care efforts. Objectives At the conclusion of this session, the participant will be able to: • understand the guideline recommendations for severe asthma; • gain understanding of the guideline recommendations for mild asthma; • understand the role of guidelines in improving asthma care and outcomes. The U.S. National Asthma Education and Prevention Program (NAEPP) was launched in 1989 and oversees the development of asthma guidelines (e.g., Expert Panel Reports) and coordinates federal asthma-related activities. The Global Initiative for Asthma (GINA) was launched in 1993 and develops resources such as evidence-based strategy documents and pocket guides for asthma management that are updated each year. The European Respiratory Society (ERS), in conjunction with the American Thoracic Society (ATS), recently completed guidelines for severe asthma. This would be the first session at the ATS International Conference to include presentations from all three different guideline committees for asthma. Chairing: L.P. Boulet, MD, Quebec, Canada J.A. Krishnan, MD, PhD, ATSF, Chicago, IL S. Khurana, MD, Rochester, NY ATS 2020 • Philadelphia, PA SUNDAY • MAY 17 59